How technology is saving babies at risk

GALACTOSEMIA  DISORDER

Without treatment, over time your child may develop cataracts and may be susceptible to infections.

“Certain enzymes help a baby in digesting milk and turning it into energy. But if the enzyme is not there or remains submissive in the first 48 to 72 hours, the baby may even die,” said

Srivastava.

“In such cases we need to withdraw milk from a baby’s diet and start giving soya milk, so that the baby can be saved. But without the screening test we won’t know.”

Victor2™D, which functions on a patented technology known as DELFIA.

“With the help of lanthanide, Victor2™D prolongs the visibility of the enzyme, allowing a trained technician to do the analysis more accurately,” said Srivastava.

“The analysis can’t be done, if you don’t get that prolonged visibility, which is why we did some interventions and got that technology patented,” said Srivastava.

Once the analysis is done, the report goes to a pediatrician, who then decides the line of treatment after seeing if there is any metabolic disorder or not.

“It requires about two to three hours of incubation time to perform this kind of analysis,” added Srivastava.

Along with GALT deficiency Victor2™D

is also used to screen congenital hyperthyroidism (CH), another common metabolic disorders, among the Indian population.

( concludes)